Hollis-Eden Pharmaceuticals Inc. Halts Neumune Development
March 16 (Reuters) - Hollis-Eden Pharmaceuticals Inc. said on Friday it will curtail further development of its radiation drug Neumune after the U.S. Department of Health and Human Services (HHS) rejected a contract proposal involving the drug last week.